乌拉地尔在心血管疾病中的临床应用

doi:10.3969/j.issn.1006-7795.2013.01.019

摘要/Abstract

摘要：

乌拉地尔是一种苯哌嗪取代的尿嘧啶衍生物,它通过阻断突触后肾上腺素α1受体,兴奋中枢5-羟色胺1受体,降低外周血管阻力,在临床中被广泛应用于高血压危象、外科手术降压及预防血压峰值等各种降压治疗;同时它具有中度的突触前α2受体兴奋作用及微弱的β1受体阻滞作用,有助于通过减少回心血量,阻断儿茶酚胺的释放,降低心脏的前后负荷,在充血性心力衰竭及缺血性心脏病等同样具有广泛潜在的应用价值。本文总结了乌拉地尔在心血管疾病中的临床应用。

关键词: 乌拉地尔, 心血管疾病, 临床应用

Abstract:

Urapidil, which is a phenyl piperazine substituted uracil derivatives, is a peripheral postsynaptic alpha 1-adrenoceptor antagonist with central agonistic action at serotonin (5-HT)-1, It was widely used in lowering blood pressure and with a wide range of indications (such as: critical hypertension, prophylaxis of hypertensive peaks and treatment of hypertension during surgery) through decreasing peripheral vascular resistance. It is also a moderate pre-synaptic alpha 2-adrenoceptor agonist with a weak beta 1-blocking effect. It can reduce the pre- and after-load of the heart by reducing the venous blood return and blocking the release of catecholamine with potential clinical applications in congestive heart failure and ischemic heart disease with few side effects. This review was written to summarize and evaluate the clinical application of urapidil in cardiovascular disease.

Key words: urapidil, cardiovascular disease, clinical application

中图分类号:

R543.3

何婧瑜, 华琦. 乌拉地尔在心血管疾病中的临床应用[J]. 首都医科大学学报, 2013, 34(1): 100-104.

HE Jingyu, HUA Qi. Clinical applications of urapidil in cardiovascular disease[J]. Journal of Capital Medical University, 2013, 34(1): 100-104.

参考文献

[1] 王琪,陈金良,申建民.静脉滴注乌拉地尔对急性心力衰竭患者血浆脑钠肽水平的影响及意义[J].临床荟萃,2008,23(4):252-254.

[2] 李静,华琦,谭静,等.卒中后急性心肌梗死患者临床特点和近期预后的分析[J].中国脑血管病杂志,2010,7(10):505-509.

[3] 吴春波,席晓芳,朱继红,等.利喜定治疗心力衰竭的临床效果观察[J].中国全科医学,2002,5(9):695-686.

[4] 田玮,朱宇清,傅研,等.利喜定治疗充血性心力衰竭临床疗效[J].山西医科大学学报,2002,33(2):123-124.

[5] 张琳,任宇超,孙慧灵.盐酸乌拉地尔、多巴胺治疗充血性心力衰竭的临床观察[J].实用心脑肺血管病杂志,2006,14(5):383-384.

[6] 周石连,周明,刘志兵,等.乌拉地尔治疗难治性心力衰竭[J].实用药物与临床, 2008,11(3):138-139.

[7] Yao D K, Jia S Q, Wang L, et al.Therapeutic effect of Urapidil on myocardial perfusion in patients with ST-elevation acute coronary syndrome[J]. Eur J Intern Med, 2009, 20(2):152-157.

[8] Kolyva C, Verhoeff B J, Spaan J A, et al. Increased diastolic time fraction as beneficial adjunct of alpha1-adrenergic receptor blockade after percutaneous coronary intervention[J]. Am J Physiol Heart Circ Physiol, 2008, 295(5):H2054-2060.

[9] Gregorini L, Marco J, Farah B,et al.Effects of selective alpha1-and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting[J]. Circulation,2002,3,106(23):2901-2907.

[10] Schad H, Heimisch W, Barankay A,et al.Effect of urapidil on the performance of ischemic myocardium in anesthetized dogs[J]. Basic Res Cardiol, 1990, 85(3):270-278.

[11] 朱芳一.乌拉地尔治疗急性充血性心力衰竭的临床观察[J].实用脑血管病杂志,2007,15(1):38-39.

[12] Arosio E, Pancera P, Sheiban I, et al.Correlation between peripheral hemodynamic changes and left ventricular diastolic function in hypertensive patients treated with urapidil[J]. J Hum Hypertens, 1996, 10(3):171-176.

[13] Pönicke K, Schlüter K D, Heinroth-Hoffmann I, et al Noradrenaline-induced increase in protein synthesis in adult rat cardiomyocytes: involvement of only alpha1Aadrenoceptors[J]. Naunyn Schmiedebergs Arch Pharmacol, 2001, 364(5):444-453.

[14] Zhang Y, Yan J, Chen K, et al. Different roles of alpha1-adrenoceptor subtypes in mediating cardiomyocyte protein synthesis in neonatal rats[J]. Clin Exp Pharmacol Physiol,2004, 31(9):626-633.

[15] Fingerle J, Sanders K H, Fotev Z. Alpha 1-receptor antagonists urapidil and prazosin inhibit neointima formation in rat carotid artery induced by balloon catheter injury[J]. Basic Res Cardiol,1991,86(Suppl 1):75-81.

[16] 沈洪,李银平,檀实,等.休克患者血浆肾上腺髓质索与血.管阻力变化的关系[J].中国危重病急救医学,1999,11(12):75-77.

[17] Audibert G, Charpentier C, Seguin-Devaux C. Improvement of donor myocardial function after treatment of autonomic storm during brain death[J]. Transplantation, 2006, 27;82(8):1031-1036.

[18] Storck J, Ochs J G, Kirsten R. Effects of urapaidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets[J]. Int J Clin Pharmacol Ther Toxicol, 1990, 28(7):303-308.

[19] Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension[J]. Metabolism, 1996,45(10):1221-1229.

[20] Krone W, Müller-Wieland D, Nägele H. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism[J]. J Cardiovasc Pharmacol,1987,10(10):199-202.

[21] Adnot S, Defouilloy C, Brun-Buisson C,et al.Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine[J]. Am Rev Respir Dis,1987, 135(2):288-293.

[22] de Leeuw P W, van Es P N, et al.Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man[J]. Drugs, 1988,35(Suppl 6):74-77.

[23] 熊德高,岑本莲.乌拉地尔、多巴胺、呋塞米静脉滴注治疗心肾综合征[J].西部医学,2007,19(5):818-820.

[24] Ohtake A, Sato S, Saitoh C, et al.Effects of tamsulosin on hypogastric nerve stimulationinduced intraurethral pressure elevation in male and female dogs under anesthesia[J]. Eur J Pharmacol, 2004, 30;497(3):327-334.

[25] Krawczyk W, Steｃ E. Urapidil (Ebrantil) use in patients on chronic hemodialysis[J]. Wiad Lek, 1990, 1;43(11):501-505.

[26] Grossman E, Ironi A N, Messerli F H.Comparative tolerability profile of hypertensive crisis treatments[J].Drug Saf, 1998, 19(2):99-122.

[27] Gosse P, Tauzin-Fin P, Sesay M B.Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose?[J]. J Hum Hypertens,2009, 23(9):605-609.

[28] Wacker J R, Wagner B K, Briese V, et al. Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil[J].Eur J Obstet Gynecol Reprod Biol, 2006, 127(2):160-165.

[29] Chidlow G, Cupido A, Melena J. Flesinoxan, a 5-HT1A receptor agonist/alpha 1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits[J]. Curr Eye Res, 2001, 23(2):144-153.

[30] Plecas-Solarovic B, Hristic-Zivkovic I, Radojevic K, et al. Chronic alpha1-adrenoreceptor blockade produces agedependent changes in rat thymus structure and thymocyte differentiation[J]. Histol Histopathol,2005, 20(3):833-841.

[31] Li S, Feng H, Zhu J, et al. Effects of urapidil and cimetidine on wedged hepatic venous pressure and systemic hemodynamics in cirrhotic patients with portal hypertension[J]. Zhonghua Wai Ke Za Zhi, 2000, 38(4):287-290.